PLK1 and prostate carcinoma: Interestingly, a previous study identified that PLK1 phosphorylation of axin2 facilitated the GSK3‐dependent phosphorylation of β‐catenin by enhancing binding between GSK3 and β‐catenin, offering a novel PLK1‐Wnt/β‐catenin signalling axis to treat prostate cancer.17, 18